SYNDEVRX

SynDevRx - the leader in the emerging field of metabo-oncology - is tackling this urgent and unmet medical need with its clinical drug evexomostat (SDX-7320)... SynDevRx is the first company developing treatments for cancer patients with baseline (or acquired) metabolic dysfunction with the only drug in clinical development that targets both the cancer and the underlying metabolic hormone dysfunction driving it - at the same time... All of us know people who have suffered and perhaps even died due to cancer. SynDevRx is dedicated to developing treatments for the rising number of patients whose cancer is associated with metabolic dysfunction.

Also known as: SynDevRx, Inc.

Primary location: Cambridge United States